
Discovery of novel allosteric medicines targeting natural hotspots on proteins to treat autoimmune diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
EmpCo Directive — September 27, 2026
We analyzed the websites of over 250,000 companies, including HotSpot Therapeutics's, to extract CSR initiatives and communications containing risky environmental claims.
Greenwashing risk score + your position within your sector
+250,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: September 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Lys Therapeutics
B
Development of first-in-class monoclonal antibodies to treat neurodegenerative and neurovascular diseases by targeting neuroinflammation and blood-brain barrier dysfunction.
Evotec
B
Drug discovery and development focusing on scientific excellence, disease understanding, and proprietary technology platforms, spanning small molecules to biotherapeutics.
Sitryx Therapeutics
C
Development of novel oral therapies to restore immune balance in autoimmune and inflammatory diseases by targeting disease-driving pathways and modulating immune cells.
Initiatives identified among leaders
Intégration de la diligence raisonnable dans gouvernance, stratégie et suivi des impacts négatifs
“La diligence raisonnable chez Evotec couvre plusie...” - EvotecRéduction de 33% émissions totales brutes et baisse intensité carbone depuis 2021
“Les émissions totales brutes ont diminué de 33% (3...” - EvotecIntégration de la diligence raisonnable dans gouvernance, stratégie et suivi des impacts négatifs
“La diligence raisonnable chez Evotec couvre plusie...” - Evotec34% of similar organizations communicate on CSR issues
+91 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports